| A Retrospective, Observational Study on the Effectiveness of Daclatasvir-Containing Regimens in Patients in KSA, UAE and Qatar (NCT03205618) | Bristol-Myers Squibb | 2016-04-26 |
| Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes" (NCT02671461) | Bristol-Myers Squibb | 2016-04-25 |
| A Study of Dasatinib Management Among CP-CML (Chronic Phase, Chronic Myeloid Leukemia) Participants Initiating Dasatinib in a Real Life Setting (NCT04089839) | Bristol-Myers Squibb | 2016-04-21 |
| Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of BMS-986189 in Healthy Subjects (NCT02739373) | Bristol-Myers Squibb | 2016-04-18 |
| An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread (NCT02658890) | Bristol-Myers Squibb | 2016-04-14 |
| A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma (NCT02714218) | Bristol-Myers Squibb | 2016-04-04 |
| An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer (NCT02632409) | Bristol-Myers Squibb | 2016-03-22 |
| An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3) (NCT02654132) | Bristol-Myers Squibb | 2016-03-18 |
| A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection (NCT02673489) | Bristol-Myers Squibb | 2016-03-15 |
| Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) (NCT02592798) | Bristol-Myers Squibb | 2016-03-09 |
| An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (NCT02617589) | Bristol-Myers Squibb | 2016-03-01 |
| Diclofenac 25mg/Paracetamol 500 mg and Diclofenac 50 mg/Paracetamol 500 mg for Patients With Pain (NCT02651363) | Bristol-Myers Squibb | 2016-03-01 |
| Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases (NCT02739386) | Bristol-Myers Squibb | 2016-02-29 |
| Treatment Patterns, Outcomes and Resource Use Study for Advanced Stage Non-Small Cell Lung Cancer (Squamous and Non-squamous) in the Kingdom of Saudi Arabia and United Arab Emirates (NCT02845089) | Bristol-Myers Squibb | 2016-02-29 |
| An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread (NCT02832167) | Bristol-Myers Squibb | 2016-02-22 |
| Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis (NCT02638948) | Bristol-Myers Squibb | 2016-02-16 |
| Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NCT02659059) | Bristol-Myers Squibb | 2016-02-15 |
| An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (NCT02581631) | Bristol-Myers Squibb | 2016-02-11 |
| A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide. (NCT02612779) | Bristol-Myers Squibb | 2016-02-09 |
| A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc) (NCT02588625) | Bristol-Myers Squibb | 2016-02-01 |
| Bleeding Events and Oral Anticoagulant Treatment in Non-Valvular Atrial Fibrillation (NCT03002740) | Bristol-Myers Squibb | 2016-01-31 |
| An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma (NCT02596035) | Bristol-Myers Squibb | 2016-01-08 |
| A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors (NCT02593786) | Bristol-Myers Squibb | 2016-01-07 |
| Regimen Optimization Study (NCT02137239) | Bristol-Myers Squibb | 2015-12-31 |
| Safety and Tolerability Study of BMS-986177 in Healthy Subjects (NCT02608970) | Bristol-Myers Squibb | 2015-12-31 |
| Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma (NCT02599402) | Bristol-Myers Squibb | 2015-12-20 |
| Safety Study of Abatacept in Rheumatoid Arthritis Participants (NCT03696173) | Bristol-Myers Squibb | 2015-12-17 |
| Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan (NCT02402699) | Bristol-Myers Squibb | 2015-12-15 |
| Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer (NCT02613507) | Bristol-Myers Squibb | 2015-12-11 |
| Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab (NCT02856451) | Bristol-Myers Squibb | 2015-12-09 |
| An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma (NCT02576509) | Bristol-Myers Squibb | 2015-12-07 |
| Treatment of Venous Thromboembolism in Real-Life Patients (NCT03087474) | Bristol-Myers Squibb | 2015-12-04 |
| Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis (NCT02576457) | Bristol-Myers Squibb | 2015-12-02 |
| Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib (NCT02733445) | Bristol-Myers Squibb | 2015-12-01 |
| Head and Neck Cancer Treatment Patterns and Outcomes Research Study in France, Germany, and Canada (NCT02705833) | Bristol-Myers Squibb | 2015-12-01 |
| A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3 (NCT02551861) | Bristol-Myers Squibb | 2015-12-01 |
| A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1) (NCT02556086) | Bristol-Myers Squibb | 2015-12-01 |
| Eliquis (VTE Treatment and Prevention of Recurrent VTE) rPMS (NCT02546817) | Bristol-Myers Squibb | 2015-11-30 |
| A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT02574078) | Bristol-Myers Squibb | 2015-11-23 |
| Long-term Epidemiological Follow-up of Non-small Cell Lung Cancer in Scandinavia (NCT02839629) | Bristol-Myers Squibb | 2015-11-23 |
| Apixaban for the Acute Treatment of Venous Thromboembolism in Children (NCT02464969) | Bristol-Myers Squibb | 2015-11-22 |
| Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis (NCT02557100) | Bristol-Myers Squibb | 2015-11-19 |
| Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors (NCT02534506) | Bristol-Myers Squibb | 2015-11-06 |
| Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea (NCT02727933) | Bristol-Myers Squibb | 2015-11-03 |
| A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine (NCT02545075) | Bristol-Myers Squibb | 2015-10-31 |
| A Study of BMS-986171 in Healthy People to Assess Safety, to Measure Blood Levels of Drug, and to Find Out What the Drug Does to the Body (NCT02538874) | Bristol-Myers Squibb | 2015-10-31 |
| Study in Patients With Unresectable And Metastatic Melanoma: The Optimize Study (NCT02780089) | Bristol-Myers Squibb | 2015-10-23 |
| A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase (NCT02369653) | Bristol-Myers Squibb | 2015-10-22 |
| Early Post-marketing Study of Daclatasvir (Daklinza) in the Treatment of Chronic Hepatitis C (CHC) in Adults (NCT03181074) | Bristol-Myers Squibb | 2015-10-21 |
| A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors (NCT02516527) | Bristol-Myers Squibb | 2015-10-16 |
| An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread. (NCT02598960) | Bristol-Myers Squibb | 2015-10-14 |
| An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors (NCT02488759) | Bristol-Myers Squibb | 2015-10-13 |
| An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy (NCT02538666) | Bristol-Myers Squibb | 2015-10-13 |
| A Study to Compare the Pharmacokinetics of Belatacept Using Active Pharmaceutical Ingredient Manufactured by Process E Relative to Process C (NCT02564497) | Bristol-Myers Squibb | 2015-10-02 |
| Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis (NCT02534636) | Bristol-Myers Squibb | 2015-10-01 |
| Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France (NCT02714855) | Bristol-Myers Squibb | 2015-10-01 |
| Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer (NCT02481830) | Bristol-Myers Squibb | 2015-09-14 |
| Effects of Abatacept in Patients With Early Rheumatoid Arthritis (NCT02504268) | Bristol-Myers Squibb | 2015-09-03 |
| CV004-007 Thrombosis Chamber Study (NCT02439190) | Bristol-Myers Squibb | 2015-09-01 |
| Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma (NCT02717364) | Bristol-Myers Squibb | 2015-08-27 |
| An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (NCT02477826) | Bristol-Myers Squibb | 2015-08-05 |
| Evaluation of the Effectiveness of Eliquis ® (Apixaban) Risk Minimization Tools in European Economic Area (EEA) Countries (NCT02339818) | Bristol-Myers Squibb | 2015-08-01 |
| HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors (NCT02536469) | Bristol-Myers Squibb | 2015-08-01 |
| A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection (NCT02496078) | Bristol-Myers Squibb | 2015-08-01 |
| Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib (NCT02297139) | Bristol-Myers Squibb | 2015-07-31 |
| Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study (NCT02546791) | Bristol-Myers Squibb | 2015-07-22 |
| Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors (NCT02472977) | Bristol-Myers Squibb | 2015-07-13 |
| YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey (NCT02224768) | Bristol-Myers Squibb | 2015-07-01 |
| Patient-Reported Efficacy of Subcutaneous (SC) Abatacept in Rheumatoid Arthritis (RA) - South Africa (NCT02598466) | Bristol-Myers Squibb | 2015-07-01 |
| Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy (NCT03438279) | Bristol-Myers Squibb | 2015-06-23 |
| Study of BMS-986158 in Subjects With Select Advanced Cancers (NCT02419417) | Bristol-Myers Squibb | 2015-06-19 |
| A Study of BMS-986148 in Patients With Select Advanced Solid Tumors (NCT02341625) | Bristol-Myers Squibb | 2015-06-19 |
| A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart (NCT02415400) | Bristol-Myers Squibb | 2015-06-04 |
| A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH) (NCT03400163) | Bristol-Myers Squibb | 2015-05-08 |
| A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH) (NCT02413372) | Bristol-Myers Squibb | 2015-05-08 |
| Early Post-Marketing Study of ELIQUIS (Apixaban) in Mexico (NCT02345343) | Bristol-Myers Squibb | 2015-05-04 |
| Study to Investigate the Effect of BMS-986142 on the Pharmacokinetics (PK) of Methotrexate and Probe Substrate Cocktail in Healthy Patients (NCT02456844) | Bristol-Myers Squibb | 2015-05-01 |
| An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC (NCT02409368) | Bristol-Myers Squibb | 2015-04-29 |
| Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery (NCT01884337) | Bristol-Myers Squibb | 2015-03-24 |
| Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (NCT02388906) | Bristol-Myers Squibb | 2015-03-16 |
| A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer (NCT02387996) | Bristol-Myers Squibb | 2015-03-09 |
| An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself (NCT02320058) | Bristol-Myers Squibb | 2015-03-05 |
| Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period (NCT02531269) | Bristol-Myers Squibb | 2015-03-01 |
| Profile and Antithrombotic Management of Patients With NVAF Attending Internal Medicine Departments in Spain (PERFILAR Study) (NCT02447341) | Bristol-Myers Squibb | 2015-03-01 |
| Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan (NCT02272803) | Bristol-Myers Squibb | 2015-02-20 |
| Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis (NCT02319031) | Bristol-Myers Squibb | 2015-02-01 |
| An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT02305563) | Bristol-Myers Squibb | 2015-01-27 |
| Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants (NCT02754154) | Bristol-Myers Squibb | 2014-12-31 |
| Taste Properties of Atazanavir and Cobicistat (NCT02307656) | Bristol-Myers Squibb | 2014-12-12 |
| A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma (NCT02252263) | Bristol-Myers Squibb | 2014-12-09 |
| Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive (NCT02279862) | Bristol-Myers Squibb | 2014-12-02 |
| Comparative Assessment of Utilization of Antiviral Therapies in Hepatitis C and Effectiveness of Daclatasvir-containing Regimens in Real-life Clinical Care in Europe (CMPASS-EU) (NCT02368522) | Bristol-Myers Squibb | 2014-12-01 |
| A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and Asunaprevir (NCT02323594) | Bristol-Myers Squibb | 2014-12-01 |
| Risk of CV Events With EFV vs. EFV-free Regimens (NCT02426866) | Bristol-Myers Squibb | 2014-12-01 |
| Study to Evaluate Safety and Efficacy in Adult Subjects With ITP (NCT02273960) | Bristol-Myers Squibb | 2014-11-17 |
| BMS-986012 in Relapsed/Refractory SCLC (NCT02247349) | Bristol-Myers Squibb | 2014-11-14 |
| Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus (NCT02265744) | Bristol-Myers Squibb | 2014-11-13 |
| Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors (Anti HER2 Fcab) (NCT02286219) | Bristol-Myers Squibb | 2014-11-04 |
| Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S (NCT02769078) | Bristol-Myers Squibb | 2014-11-01 |
| An Observational Study of the Functional Capacity of Heart Failure (NCT02350114) | Bristol-Myers Squibb | 2014-11-01 |